–
Статьи в журналах
-
- 2017 Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- Bruix Jordi, Qin Shukui, Merle Philippe, Granito Alessandro, Huang Yi-Hsiang, Bodoky György, Pracht Marc, Yokosuka Osamu, Rosmorduc Olivier, Breder Valeriy, Gerolami René, Masi Gianluca, Ross Paul J., Song Tianqiang, Bronowicki Jean-Pierre, Ollivier-Hourmand Isabelle, Kudo Masatoshi, Cheng Ann-Lii, Llovet Josep M., Finn Richard S., LeBerre Marie-Aude, Baumhauer Annette, Meinhardt Gerold, Han Guohong
- в журнале The Lancet, издательство The Lancet Publishing Group (United Kingdom), том 389, № 10064, с. 56-66 DOI